Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 13/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14353248 | 0.98 | HPGD (1.00) | HPGDALDH1A1HTTKDM4EKMT2A | |
| SCHEMBL2849468 | 0.84 | HPGD (0.71) | HPGDALDH1A1HTTKDM4EKMT2A | |
| SCHEMBL2851419 | 0.84 | HPGD (1.00) | HPGDALDH1A1HTTKDM4EKMT2A | |
| SCHEMBL2855635 | 0.83 | HPGD (1.00) | HPGDALDH1A1HTTKDM4EKMT2A | |
| SCHEMBL2858672 | 0.83 | HPGD (1.00) | HPGDALDH1A1HTTKDM4EKMT2A | |
| SCHEMBL2857892 | 0.82 | HPGD (0.67) | HPGDALDH1A1HTTKDM4EKMT2A | |
| SCHEMBL2849299 | 0.81 | HPGD (0.70) | HPGDALDH1A1HTTKDM4EKMT2A | |
| SCHEMBL2854306 | 0.81 | HPGD (1.00) | HPGDALDH1A1HTTKDM4EKMT2A | |
| SCHEMBL14153756 | 0.81 | HPGD (0.97) | HPGDALDH1A1HTTKDM4EKMT2A | |
| SCHEMBL13513678 | 0.80 | HPGD (0.64) | HPGDALDH1A1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197658-A1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-05 | — | — | US | claimed |
| EP-1615647-B1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-01-20 | — | — | EP | claimed |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | claimed |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| US-20080153807-A1 | Pharmaceutical Use of Fused 1,2,4-Triazoles | NOVO NORDISK A/S (DK) | 2008-06-26 | — | — | US | claimed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060106008-A1 | Pharmaceutical use of fused 1,2,4-triazoles | NOVO NORDISK A/S (DK) | 2006-05-18 | — | — | US | claimed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | claimed |
| EP-1615667-A2 | COMBINATIONS OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| US-20230167447-A1 | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | GENETIC INTELLIGENCE INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167447-A1 | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | GENETIC INTELLIGENCE INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-20100197658-A1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-7723323-B2 | Pharmaceutical use of fused 1,2,4-triazoles | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1615667-A2 | COMBINATIONS OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089380-A2 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106008-A1 | Pharmaceutical use of fused 1,2,4-triazoles | HSD3B1, HSD11B1, HSD11B2 | HPGD 63/4885ALDH1A1 166/4885HTT 3466/4885 |
| US-20080153807-A1 | Pharmaceutical Use of Fused 1,2,4-Triazoles | HSD3B1, HSD11B1, HSD11B2 | HPGD 63/4885ALDH1A1 166/4885HTT 3466/4885 |
| US-20230167447-A1 | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | FNIP1, FN1, TNNC1 | HPGD 3545/4885ALDH1A1 4324/4885HTT 6/4885 |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | HPGD 119/4885ALDH1A1 253/4885HTT 4448/4885 |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | HSD11B1, HSD11B2, HSD17B1 | HPGD 84/4885ALDH1A1 74/4885HTT 2515/4885 |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | HPGD 84/4885ALDH1A1 74/4885HTT 2515/4885 |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HSD11B1, HSD17B1, NR3C1 | HPGD 119/4885ALDH1A1 253/4885HTT 4448/4885 |
| US-20100197658-A1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HSD3B1, HSD11B2, HSD3B2 | HPGD 71/4885ALDH1A1 528/4885HTT 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.